drugset / Trial / NCT01429337
PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this international study was to assess the effect of varying degrees of impaired hepatic function compared to a normal hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of midostaurin.
Timeline
- Start
- 2011-03-07
- Primary completion
- 2020-04-13
- Completion
- 2020-05-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midostaurin | Small molecule | 50 mg | Oral |
Indications
No indication recorded.